The ongoing phase 3 INDEPENDENCE trial of luspatercept in combination with a JAK2 inhibitor will shed additional light on this approach to anemia management in transfusion-dependent patients with myelofibrosis [60]. The gene discussed is JAK2; the disease is myelofibrosis.